Immediate procurement and contract research access to validated botanical extraction protocols, preclinical screening assays, and regulatory-approved production processes.
The worldwide healthcare and preventative medicine sector is experiencing an unprecedented structural transition. Consumer demand for clean-label, bioavailable, and clinically supported therapeutic solutions has forced pharmaceutical and nutraceutical brands to move away from generic blending facilities toward integrated CRO-CDMO partnerships. Modern health enterprises require verified phytochemical integrity, absolute supply-chain transparency, and defensible clinical data to navigate international regulatory hurdles.
Global regulatory bodies—including the United States FDA (21 CFR Part 111 & Part 211), the European Medicines Agency (EMA), and China’s NMPA—are synchronizing identification standards. Modern buyers require botanical fingerprinting (HPTLC/HPLC) to guarantee zero adulteration and consistent pharmacological potency across all production batches.
Health claims in the modern functional food, dietary supplement, and phyto-drug sectors are obsolete without rigorous empirical backing. Enterprise procurers actively seek CDMOs capable of organizing controlled in vitro cellular mechanisms, GLP-compliant rodent animal models, and ethical human clinical trials (Phase I–IV) directly attached to manufactured lots.
Geopolitical turbulence and climate variability have exposed severe vulnerabilities in raw botanical procurement. MedGence solves this through geobotanical origin mapping, evaluating active chemical densities across micro-climates, soil compositions, and harvest calendars to stabilize production economics and guarantee commercial availability.
MedGence (Yineng Pharma) provides an uninterrupted continuum connecting molecular discovery to commercial cGMP production. Enterprise clients can engage our infrastructure as a turnkey end-to-end CDMO partner or commission individual analytical and regulatory work packages.
High-throughput identification of bioactive alkaloids, polyphenols, flavonoids, and polysaccharides targeting specific biological pathways (metabolic, immunological, cognitive, or anti-aging mechanisms).
Systematic quantification of secondary metabolite variance across geographical origins, seasonal harvesting windows, and anatomical plant parts (root, leaf, rhizome, bark) to maximize yield efficiency.
Validation of chromatographic fingerprinting standards using HPLC, HPTLC, GC-MS, and LC-MS/MS compliant with USP, EP, ChP, and JP pharmacopeias, establishing irrevocable purity baselines.
Pilot-scale parameter optimization covering solvent systems, critical temperatures, column adsorption kinetics, ultrafiltration, and vacuum drying to prevent molecular degradation.
Engineering stable delivery matrices that resolve bioavailability limitations, hygroscopic moisture instability, active ingredient oxidation, and off-taste botanical profiles.
Comprehensive GLP-compliant toxicological screening: Acute LD50, sub-acute 90-day dietary toxicity, chronic toxicity, and Ames test genotoxicity profiling for regulatory submissions.
Mechanistic bioassays using primary cell cultures to map anti-inflammatory cytokines, enzymatic inhibition (e.g., alpha-glucosidase), ROS radical neutralization, and cellular viability.
Animal disease model testing (rodent metabolic models, cognitive decline, hepatic protection) providing statistically validated preclinical dossiers to de-risk investment before human trials.
End-to-end human trials execution: double-blind, randomized, placebo-controlled clinical protocols for functional dietary claim substantiation and NDA pharma regulatory filings.
Translating ancient clinical wisdom into reproducible molecular mechanisms, backed by the successful modernization of 83 classic Chinese medicine multi-herb master formulas.
Bulk production of standardized plant extracts, high-purity single active isolates, purified volatile oils, concentrated liquids, and bio-fermented botanicals under strict IP quarantine.
High-speed commercial encapsulation, multi-layer tableting, softgel encapsulation, liquid shot sterile bottling, and moisture-barrier granule sachet packaging in ISO/GMP suites.
MedGence (Yineng Pharma) operates one of the Asia-Pacific region's most comprehensive botanical research institutes and CDMO manufacturing complexes. Our technical capabilities are validated by commercial contracts with Tier-1 pharmaceutical conglomerates and national medical research hospitals.
We solve macro-level supply chain complexity by offering versatile formulation modalities engineered for immediate shelf readiness, global customs clearance, and accelerated consumer adoption.
Precision hard-gelatin and HPMC vegetarian capsules, micro-tablets, enteric-coated bi-layer tablets, effervescent discs, and specialized moisture-resistant granules packaged in nitrogen-flushed blisters or recyclable bottles.
Micro-encapsulated oil softgels, liposomal suspensions, sublingual dropper tinctures, and sterile oral liquid health shots (10ml to 50ml ampoules/bottles) designed for rapid systemic absorption and pleasant palatability.
Instantized micro-fine soluble powders, instant botanical teas, meal replacement fortified blends, and vacuum freeze-dried botanical matrices packaged in stick packs, gusseted pouches, or bulk HDPE drums.
International health brand expansion hinges upon bulletproof compliance dossiers. MedGence maintains an unyielding quality infrastructure certified against the world’s most stringent regulatory frameworks.
Our collaborative and proprietary manufacturing cleanrooms strictly follow US FDA 21 CFR Part 111 (Dietary Supplements), 21 CFR Part 211 (cGMP for Pharmaceuticals), and European Good Manufacturing Practices (EU cGMP Annex 1).
Every commercial client benefits from segregated cleanroom runs, dedicated batch record numbers, and legally enforceable mutual NDA agreements. We do not manufacture competing proprietary house brands, preventing conflicts of interest.
Full-spectrum documentation support for market authorization: Certificate of Analysis (CoA), Master Batch Records (MBR), Process Validation Protocols, Accelerated Stability Reports (ICH Q1A), and Non-GMO/Allergen/Heavy Metal testing suites.
Over 14+ years, our scientific research leadership and CDMO production output have supported China's largest listed pharmaceutical conglomerates and accredited academic medical institutions.
Tongrentang Group
CR Sanjiu
Sunflower Pharma
Livzon Group
Dihon Pharma
Golden Throat
Yangtzi River Pharma
Beihai Gofar
Humanwell Group
SCIMYTH Pharma
Hanfang Pharma
Luoxin Pharma
Zhongsheng Pharma
Brilliance Herbal
Apeloa Pharma
Heng Chang Pharma
Baotou TCM
Kamp Medicine
To maintain information gain leadership for our enterprise clientele, MedGence invests heavily in emerging biopharmaceutical methodologies that redefine yield efficiency, environmental sustainability, and pharmacokinetic performance.
Integrating machine-learning chemometric software with high-resolution mass spectrometers to instantly match uncharacterized botanical fractions against vast therapeutic protein target databases, compressing initial hit discovery timelines by up to 65%.
Replacing high-emission organic solvents with state-of-the-art Supercritical Carbon Dioxide (scCO2) and pressurized water extraction loops, yielding solvent-free botanical compounds that surpass European green chemistry regulations.
Overcoming the poor water-solubility of key botanical molecules (curcumin, resveratrol, berberine) via thermodynamic lipid formulation engineering, boosting in vivo intestinal bioavailability by 300% to 800%.
Direct answers regarding commercial contracting, tech transfer timelines, regulatory documentation, minimum order quantities (MOQs), and intellectual property protection.
Access standard commercial protocols or request customized research quotes from our technical team. Each work package yields tangible analytical and physical deliverables.
Collaborate directly with our principal phytochemists and regulatory affairs directors. Share your target biological claims, compound specifications, or commercial batch forecasts to receive a rigorous technical study scope within 48 hours.
